Insulet Corp. (PODD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 904 | 1,099 | 1,305 | 1,697 | 2,072 | 2,708 | 3,054 | 3,291 |
| Operating profit | $m | 474 | 516 | ||||||
| Net profit | $m | 7 | 17 | 5 | 206 | 418 | 247 | 375 | 467 |
| EPS reported | $ | 3.48 | 5.35 | ||||||
| Operating cashflow per share | $ | 8.09 | 7.38 | ||||||
| Capex per share | $ | 2.72 | 3.07 | ||||||
| FCF per share | $ | 5.37 | 4.30 | ||||||
| Free cash flow | $m | 378 | 298 | ||||||
| Net debt | $m | 286 | 414 | ||||||
| Book value equity | $m | 1,515 | 1,422 | ||||||
| Book value per share | $ | 21.08 | 20.49 | ||||||
| Number of shares | m | 71.89 | 69.4 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 81.68 | 25.44 | ||||||
| P/B LTM | x | 13.20 | 14.06 | ||||||
| P/S LTM | x | 7.38 | 6.55 | ||||||
| P/FCF LTM | x | 52.94 | 67.03 | ||||||
| EV/EBITDA LTM | x | 38.19 | 31.92 | ||||||
| EV/Sales LTM | x | 7.51 | 3.39 | ||||||
| Earnings Yield LTM | % | +1.22% | +3.93% | ||||||
| FCF Yield | % | +1.89% | +1.49% | ||||||
| Quality | |||||||||
| ROE | % | +16.31% | +26.69% | ||||||
| ROIC | % | +13.62% | +16.04% | ||||||
| Operating margin | % | +17.50% | +16.89% | ||||||
| Gross margin | % | +71.63% | +71.08% | ||||||
| FCF/Sales | % | +13.95% | +9.77% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -39.79% | -7.44% | ||||||
| Sales Growth YoY | % | +30.73% | +47.40% | ||||||
| Net Income Growth YoY | % | -40.93% | -10.28% | ||||||
| FCF Growth | % | +23.67% | -2.32% | ||||||
| Operating Profit Growth | % | +53.38% | +66.98% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.36 | 0.31 | ||||||
| Net Debt/EBITDA | x | 0.63 | 0.65 | ||||||
| EBIT/Net interest | x | 5.94 | 8.14 | ||||||
| Net debt/market cap | % | +5.01% | +9.55% | ||||||
| Net debt/Equity | x | 0.19 | 0.29 | ||||||
| Gross debt/equity | x | 0.69 | 0.67 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free